Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jeetesh Bhardwa, Miles Goldstraw, Sevasti Tzortzis & Roger Kirby. (2007) Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy 8:9, pages 1337-1344.
Read now
Read now
Sheila A Doggrell. (2004) After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy 5:9, pages 1957-1964.
Read now
Read now
Jay Khastgir, Manit Arya, Iqbal S Shergill, Jas S Kalsi, Sux Minhas & AnthonyR Mundy. (2002) Current concepts in the pharmacotherapy of benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy 3:12, pages 1727-1737.
Read now
Read now
Articles from other publishers (48)
. (2019) Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. Aktuelle Urologie 50:S 01, pages s11-s59.
Crossref
Crossref
Nobuki Sakauchi, Hideki Furukawa, Junya Shirai, Ayumu Sato, Haruhiko Kuno, Reiko Saikawa & Masato Yoshida. (2017) Identification of 3,4-dihydro-2 H -thiochromene 1,1-dioxide derivatives with a phenoxyethylamine group as highly potent and selective α 1D adrenoceptor antagonists. European Journal of Medicinal Chemistry 139, pages 114-127.
Crossref
Crossref
Fang Xu, Hong Chen, Jingyi Xu, Xue Liang, Xuelan He, Binhao Shao, Xianqiang Sun, Bing Li, Xiaoliang Deng & Mu Yuan. (2015) Synthesis, structure–activity relationship and biological evaluation of novel arylpiperzines as α1A/1D-AR subselective antagonists for BPH. Bioorganic & Medicinal Chemistry 23:24, pages 7735-7742.
Crossref
Crossref
Makoto Yono, Yasuhiro Yamamoto, Aya Imanishi, Atsushi Fukagawa, Jamshid Latifpour & Masaki Yoshida. (2009)
Short- and long-term effects of silodosin, a selective α
1A
-adrenoceptor antagonist, on ejaculatory function in rats
. BJU International 103:12, pages 1680-1685.
Crossref
Crossref
Imre Romics. (2008) Conservative treatment of benign prostatic hyperplasia. Orvosi Hetilap 149:40, pages 1875-1880.
Crossref
Crossref
Yoshiyuki Kojima, Shoichi Sasaki, Hitomi Shinoura, Masa Hayase, Yasue Kubota, Yutaro Hayashi, Gozoh Tsujimoto & Kenjiro Kohri. (2007) Change of expression levels of alpha1‐adrenoceptor subtypes by administration of alpha1d‐adrenoceptor‐subtype‐selective antagonist naftopidil in benign prostate hyperplasia patients. The Prostate 67:12, pages 1285-1292.
Crossref
Crossref
Romain Caremel, Baptiste Albouy, Aude De Fourmestraux, Yves Tanneau & Philippe Grise. (2007) Premiers résultats de la toxine botulique dans le traitement de l’hyperplasie bénigne de la prostate. Progrès en Urologie 17:4, pages 796-800.
Crossref
Crossref
Stephen S Connolly & John M Fitzpatrick. (2007) Medical treatment of benign prostatic hyperplasia. Postgraduate Medical Journal 83:976, pages 73-78.
Crossref
Crossref
Zhaoying Xue, Yuanfang Zhang, Qiang Ding, Zhishong He, Jiangong Wang & Ke Xu. (2007) Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: A study in Chinese patients. International Journal of Urology 14:2, pages 118-122.
Crossref
Crossref
Yao-Chi Chuang, Chao-Cheng Huang, Hong-Yo Kang, Po-Hui Chiang, Fernando Demiguel, Naoki Yoshimura & Michael B. Chancellor. (2006) Novel Action of Botulinum Toxin on the Stromal and Epithelial Components of the Prostate Gland. Journal of Urology 175:3, pages 1158-1163.
Crossref
Crossref
Makoto Yono, Harris E. FosterJr.Jr., David Shin, Shrikant Mane & Jamshid Latifpour. (2005) Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling. Life Sciences 77:4, pages 470-479.
Crossref
Crossref
John M. Fitzpatrick & Francois Desgrandchamps. (2005) The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU International 95:4, pages 575-579.
Crossref
Crossref
HARRIS E. FOSTER, MAKOTO YONO, DAVID SHIN, WATARU TAKAHASHI, MEHDI POURESMAIL, PARVIZ AFIATPOUR & JAMSHID LATIFPOUR. (2004)
EFFECTS OF CHRONIC ADMINISTRATION OF DOXAZOSIN ON α
1
-ADRENOCEPTORS IN THE RAT PROSTATE
. Journal of Urology 172:6 Part 1, pages 2465-2470.
Crossref
Crossref
Anthony R. HaightAnne E. BaileyWilliam S. BakerMichael H. CainRichard R. CoppJohn A. DeMatteiKelley L. FordRodger F. HenryMargaret C. HsuRobert F. KeyesSteven A. KingMaureen A. McLaughlinLaura M. MelcherWilliam R. NadlerPatricia A. OliverShyamal I. ParekhHemant H. PatelLouis S. SeifMike A. StaegerGregory S. WayneSteven J. WittenbergerWeijiang Zhang. (2004) A Scaleable Synthesis of Fiduxosin. Organic Process Research & Development 8:6, pages 897-902.
Crossref
Crossref
Makoto Yono, Harris E Foster, Jr.David Shin, Wataru Takahashi, Mehdi Pouresmail & Jamshid Latifpour. (2004)
Doxazosin-induced up-regulation of α
1A
-adrenoceptor mRNA in the rat lower urinary tract
. Canadian Journal of Physiology and Pharmacology 82:10, pages 872-878.
Crossref
Crossref
Makoto Yono, Harris E. FosterJr.Jr., David Shin, Wataru Takahashi, Mehdi Pouresmail & Jamshid Latifpour. (2004) Doxazosin treatment causes differential alterations of α1-adrenoceptor subtypes in the rat kidney, heart and aorta. Life Sciences 75:21, pages 2605-2614.
Crossref
Crossref
R.S. Kirby, S. Quinn, S. Mallen & D. Jensen. (2004) Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. International Journal of Clinical Practice 58:1, pages 6-10.
Crossref
Crossref
R.S. Kirby. (2003) A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU International 91:1, pages 41-44.
Crossref
Crossref
Timothy D. Moon. 2003. Atlas of the Prostate. Atlas of the Prostate
25
39
.
JM Flack. (2002) THE EFFECT OF DOXAZOSIN ON SEXUAL FUNCTION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, HYPERTENSION, OR BOTH. International Journal of Clinical Practice 56:7, pages 527-530.
Crossref
Crossref
R. Berges. 2002. Pharmakotherapie in der Urologie. Pharmakotherapie in der Urologie
269
284
.
Michael D. Meyer, Robert J. Altenbach, Hao Bai, Fatima Z. Basha, William A. Carroll, James F. Kerwin, Suzanne A. Lebold, Edmund Lee, John K. Pratt, Kevin B. Sippy, Karin Tietje, Michael D. Wendt, Michael E. Brune, Steven A. Buckner, Arthur A. Hancock & Irene Drizin. (2001)
Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[
e
]isoindole α
1A
Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia
. Journal of Medicinal Chemistry 44:12, pages 1971-1985.
Crossref
Crossref
R.S. Kirby, M. Andersen, P. Gratzke, C. Dahlstrand & K. Høye. (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU International 87:3, pages 192-200.
Crossref
Crossref
Gee-Hong Kuo, Catherine Prouty, William V Murray, Virginia Pulito, Linda Jolliffe, Peter Cheung, Sally Varga, Mary Evangelisto & Charles Shaw. (2000) Design, synthesis and biological evaluation of pyridine-phenylpiperazines: A novel series of potent and selective α1a-adrenergic receptor antagonist. Bioorganic & Medicinal Chemistry 8:9, pages 2263-2275.
Crossref
Crossref
Gee-Hong Kuo, Catherine Prouty, William V. Murray, Virginia Pulito, Linda Jolliffe, Peter Cheung, Sally Varga, Mary Evangelisto & Jian Wang. (2000)
Design, Synthesis, and Structure−Activity Relationships of Phthalimide-Phenylpiperazines: A Novel Series of Potent and Selective α
1
a
-Adrenergic Receptor Antagonists
. Journal of Medicinal Chemistry 43:11, pages 2183-2195.
Crossref
Crossref
Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Stephen Condon, Steven W. Elmore, James F. Kerwin, Kevin B. Sippy, Karin Tietje, Michael D. Wendt, Arthur A. Hancock, Michael E. Brune, Steven A. Buckner & Irene Drizin. (2000)
Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[
e
]isoindole α
1A
Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
. Journal of Medicinal Chemistry 43:8, pages 1586-1603.
Crossref
Crossref
Klaus Höfner, Udo Jonas & Christian G. Stief. 2000. Benigne Prostatahyperplasie. Benigne Prostatahyperplasie
557
580
.
D. Bach, K. Höfner, U. Jonas, C. Stief & U. W. Tunn. 2000. Benigne Prostatahyperplasie. Benigne Prostatahyperplasie
237
313
.
SCOTT A. MacDIARMID, ROBERT T. EMERY, SCOTT F. FERGUSON, REBECCA McGUIRT-FRANKLIN, WILLIAM J. McINTYRE & DON E. JOHNSON. (1999) A RANDOMIZED DOUBLE-BLIND STUDY ASSESSING 4 VERSUS 8 MG. DOXAZOSIN FOR BENIGN PROSTATIC HYPERPLASIA. The Journal of Urology, pages 1629.
Crossref
Crossref
SCOTT A. MacDIARMID, ROBERT T. EMERY, SCOTT F. FERGUSON, REBECCA McGUIRT-FRANKLIN, WILLIAM J. McINTYRE & DON E. JOHNSON. (1999) A RANDOMIZED DOUBLE-BLIND STUDY ASSESSING 4 VERSUS 8 MG. DOXAZOSIN FOR BENIGN PROSTATIC HYPERPLASIA. Journal of Urology 162:5, pages 1629-1632.
Crossref
Crossref
Robert M. Guthrie & Richard L. Siegel. (1999) A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the hypertension and BPH intervention trial (HABIT). Clinical Therapeutics 21:10, pages 1732-1748.
Crossref
Crossref
Ahmed Fawzy, Angela Hendry, Eileen Cook & Francisco Gonzalez. (2002) Long‐term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. International Journal of Urology 6:7, pages 346-354.
Crossref
Crossref
Ahmed Fawzy, Vijay Vashi, Menger Chung, Norma Dias & Michael Gaffney. (1999) Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology 53:2, pages 329-335.
Crossref
Crossref
RS Kirby. (1998) EXPANDING ROLE OF ALPHA ADRENOCEPTOR BLOCKADE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. International Journal of Clinical Practice 52:6, pages 402-407.
Crossref
Crossref
RS Kirby. (1998) MORNING VERSUS EVENING DOSING WITH DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA: PHARMACOKINETICS, EFFICACY AND SAFETY. International Journal of Clinical Practice 52:2, pages 75-77.
Crossref
Crossref
Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, Steven W. Elmore, Paul P. Ehrlich, Suzanne A. Lebold, Karin Tietje, Kevin B. Sippy, Michael D. Wendt, Daniel J. Plata, Fred Plagge, Steven A. Buckner, Michael E. Brune, Arthur A. Hancock & James F. Kerwin. (1997)
Synthesis and Pharmacological Characterization of 3-[2-((3a
R
,9b
R
)-
cis
-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1
H
- benz[
e
]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-
d
]pyrimidine- 2,4(1
H
,3
H
)-dione (A-131701): A Uroselective α
1A
Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia
. Journal of Medicinal Chemistry 40:20, pages 3141-3143.
Crossref
Crossref
R.S. KIRBY. (2014) Medical therapy for benign prostatic hyperplasia: the road ahead. British Journal of Urology 79:S1, pages 92-96.
Crossref
Crossref
Herbert Lepor, Steven A. Kaplan, Ira Klimberg, David F. Mobley, Ahmed Fawzy, Michael Gaffney, Kathleen Ice & Norma Dias. (1997) Doxazosin for Benign Prostatic Hyperplasia. The Journal of Urology, pages 525-530.
Crossref
Crossref
Herbert LeporSteven A. KaplanIra KlimbergDavid F. MobleyAhmed FawzyMichael GaffneyKathleen IceNorma Dias. (1997) Doxazosin for Benign Prostatic Hyperplasia: Long-term Efficacy and Safety in Hypertensive and Normotensive Patients. Journal of Urology 157:2, pages 525-530.
Crossref
Crossref
Steven A. Kaplan & Norman M. Kaplan. (1996) Alpha-blockade: Monotherapy for hypertension and benign prostatic hyperplasia. Urology 48:4, pages 541-550.
Crossref
Crossref
H. Metzker, M. Kieser & U. Hölscher. (2014) Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH). Der Urologe B 36:4, pages 292-300.
Crossref
Crossref
Glenn S. Gerber, Jae H. Kim, Barbara A. Contreras, Gary D. Steinberg & Daniel B. Rukstalis. (1996) An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 47:6, pages 840-844.
Crossref
Crossref
JL Pool. (1996) DOXAZOSIN: A NEW APPROACH TO HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA. International Journal of Clinical Practice 50:3, pages 154-163.
Crossref
Crossref
Steven A. Kaplan, Patricia Meade-D'alisera, Sofia Quinones & Katherine A. Soldo. (1995) Doxazos1n in physiologically and pharmacologically normotensive men with benign prostat1c hyperplasia. Urology 46:4, pages 512-517.
Crossref
Crossref
Lars M. Eri & Kjell J. Tveter. (1995) Alpha-Blockade in the Treatment of Symptomatic Benign Prostatic Hyperplasia. Journal of Urology 154:3, pages 923-934.
Crossref
Crossref
J. Tseng-Crank, T. Kost, A. Goetz, S. Hazum, K.M. Roberson, J. Haizlip, N. Godinot, C.N. Robertson & D. Saussy. (1995) The α1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. British Journal of Pharmacology 115:8, pages 1475-1485.
Crossref
Crossref
Ahmed Fawzy, Karl Braun, George P. Lewis, Michael Gaffney & Kathleen Ice. (1995) Doxazosin in the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients. The Journal of Urology, pages 105-109.
Crossref
Crossref
Ahmed FawzyKarl BraunGeorge P. LewisMichael GaffneyKathleen Ice. (1995) Doxazosin in the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients: A Multicenter Study. Journal of Urology 154:1, pages 105-109.
Crossref
Crossref